_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Doctors at Yashoda Hospitals Hyderabad perform rare operation
Prashant comes with over 17 years of experience in the health, health insurance and other allied healthcare sectors
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
Over the next three years, BASF will continue to support Beyond Suncare by supplying the required raw materials free of charge and by providing technical expertise to further improve the formulation
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
